Cancer News and Research

Latest Cancer News and Research

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

11 Dec 2012

Magnetic resonance ultrasound fusion biopsy may improve prostate cancer diagnosis

Diagnosis of prostate cancer remains imperfect. Current methods of prostate biopsy are limited by over detection of slow-growing tumors and under detection of clinically relevant cancers. Investigators at the University of California-Los Angeles Department of Urology have found that a new technique of targeted biopsy in a clinic setting, using local anesthesia, may improve diagnosis and aid in selecting which patients are suitable for active surveillance and which need focal therapy (noninvasive techniques for destroying small tumors within the prostate).

11 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Lack of TDP-43 protein can lead to frontotemporal dementia/ALS

Researchers at Mayo Clinic in Florida have uncovered a toxic cellular process by which a protein that maintains the health of neurons becomes deficient and can lead to dementia.

11 Dec 2012

Easy ways to prevent dry skin

What do cleansers, alcohol and coffee have in common? They are the worst enemies of your skin during winter, sucking out the moisture from your skin and making it extremely dry and itchy.

11 Dec 2012

Transplanting spermatogonial stem cells could restore fertility in male cancer patients

Radiation and chemotherapy can pack a powerful punch against all kinds of cancers. Those who survive, however, are often left with bad news: Their treatments have rendered them infertile.

11 Dec 2012

Intensified chemotherapy can reduce risk of relapse in pediatric patients with B-ALL

Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.

11 Dec 2012

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

11 Dec 2012

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

Liposarcoma, the most common type of sarcoma, is an often lethal form of cancer that develops in fat cells. It is particularly deadly, in part, because the tumors are not consistently visible with positron emission tomography (PET) scans that use a common probe called FDG and because they frequently do not respond to chemotherapy.

11 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Merrimack Pharmaceuticals, Inc. today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer.

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

UNM study to understand why and how DNA repair mechanisms go awry in cancer cells

DNA, like houses and cars, needs ongoing maintenance. Rays of ultraviolet sunlight, chemical pollutants and normal biochemical processes in the cell can damage it. Cells routinely repair this damage before making proteins or copying DNA for cell division. The repairs are remarkably accurate in normal cells but cancer cells make far more mistakes in fixing their DNA.

11 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Biogen Idec and Isis Pharmaceuticals, Inc. today announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.

11 Dec 2012

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

11 Dec 2012

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies.

11 Dec 2012

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

10 Dec 2012

Boston College professor to research into new drugs that can prevent onset of toxoplasmosis

The American Cancer Society has awarded a four-year, $720,000 grant to Boston College Associate Professor of Biology Marc-Jan Gubbels for research into potential new drugs that can prevent the onset of toxoplasmosis in cancer patients with weakened immune systems.

10 Dec 2012

Cancer News and Research

Latest Cancer News and Research

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

Magnetic resonance ultrasound fusion biopsy may improve prostate cancer diagnosis

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Lack of TDP-43 protein can lead to frontotemporal dementia/ALS

Easy ways to prevent dry skin

Transplanting spermatogonial stem cells could restore fertility in male cancer patients

Intensified chemotherapy can reduce risk of relapse in pediatric patients with B-ALL

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

UNM study to understand why and how DNA repair mechanisms go awry in cancer cells

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

Boston College professor to research into new drugs that can prevent onset of toxoplasmosis

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in